Surgical management of cholangiocarcinoma

Abstract

Cholangiocarcinoma (CCA) is a rare but lethal tumor that arises from the intrahepatic, perihilar, or extrahepatic bile ducts. Complete surgical resection remains the only chance at long-term survival. Unfortunately, most cases of CCA are clinically silent until late in the disease process, and, combined with the lack of effective screening tests, many CCAs present as unresectable tumors. CCA workup typically includes a multiphasic chest, abdominal, and pelvic imaging, liver function tests, and tumor markers (CEA, CA 19-9). Tissue diagnosis is encouraged but not always necessary. In certain situations, esophagogastroduodenoscopy, colonoscopy, and mammography are recommended. If resectable, intrahepatic CCAs and perihilar CCAs require a hepatectomy ranging from a wedge resection to an extended hepatectomy with reconstruction depending on the location and tumor size. In certain specialized centers, portal vein and hepatic artery reconstruction can be performed with good outcomes and acceptable morbidity. For resectable extrahepatic CCAs, a pancreaticoduodenectomy is recommended. Traditionally, few effective adjuvant options have existed for patients after surgery. However, recent randomized controlled trials support the use of either adjuvant chemotherapy or chemoradiation therapy after surgical resection. In select patients, intra-arterial therapy options such as transarterial chemoembolization, hepatic artery infusion therapy, or yttrium-90 radioembolization, as well as liver transplant, are effective treatment modalities. Improved surgical techniques, regionalization of care to high-volume centers, and appropriate application of preoperative optimization techniques have safely expanded the candidates of potentially resectable patients and improved patient outcomes.

Keywords

Cholangiocarcinoma / hepatectomy / pancreaticoduodenectomy / bile duct / intrahepatic / extrahepatic / perihilar

References

[1] Patel N.Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states.Cureus2019;11:e3962 PMCID:PMC6436669

[2] Gad MM,Faisaluddin M.Epidemiology of cholangiocarcinoma; United States incidence and mortality trends.Clin Res Hepatol Gastroenterol2020;44:885-93

[3] Forner A,Rengo M,Ponz-Sarvisé M.Clinical presentation, diagnosis and staging of cholangiocarcinoma.Liver Int2019;39 Suppl 1:98-107

[4] Banales JM,Lamarca A.Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nat Rev Gastroenterol Hepatol2020;17:557-88 PMCID:PMC7447603

[5] Hyder O,Sotiropoulos GC.Recurrence after operative management of intrahepatic cholangiocarcinoma.Surgery2013;153:811-8 PMCID:PMC3980567

[6] DeOliveira ML,Cameron JL.Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.Ann Surg2007;245:755-62 PMCID:PMC1877058

[7] Krasinskas AM.Cholangiocarcinoma.Surg Pathol Clin2018;11:403-29

[8] Nagtegaal ID,Klimstra D.WHO Classification of Tumours Editorial BoardThe 2019 WHO classification of tumours of the digestive system.Histopathology2020;76:182-8 PMCID:PMC7003895

[9] Blechacz B,Roskams T.Clinical diagnosis and staging of cholangiocarcinoma.Nat Rev Gastroenterol Hepatol2011;8:512-22 PMCID:PMC3331791

[10] Chun YS,Vauthey JN.8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers.Ann Surg Oncol2018;25:845-7

[11] Bismuth H,Diamond T.Management strategies in resection for hilar cholangiocarcinoma.Ann Surg1992;215:31-8 PMCID:PMC1242367

[12] Jarnagin WR,DeMatteo RP.Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.Ann Surg2001;234:507-17; discussion 517-9 PMCID:PMC1422074

[13] Matsuo K,Ito K.The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients.J Am Coll Surg2012;215:343-55

[14] Chaiteerakij R,Marrero CR.A new clinically based staging system for perihilar cholangiocarcinoma.Am J Gastroenterol2014;109:1881-90 PMCID:PMC4341961

[15] Nguyen Canh H,Yamamura M.Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.Histopathology2021;79:731-50

[16] Deoliveira ML,Nimura Y.New staging system and a registry for perihilar cholangiocarcinoma.Hepatology2011;53:1363-71

[17] Yamashita S,Imura S.A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2.World J Surg Oncol2021;19:142 PMCID:PMC8106133

[18] Welzel TM,El-Serag HB.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.Clin Gastroenterol Hepatol2007;5:1221-8 PMCID:PMC2083573

[19] Jing W,Zhou X.Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis.Eur J Cancer Prev2012;21:24-31

[20] Sahani D,Tannabe KK,Mueller PR.Thorotrast-induced cholangiocarcinoma: case report.Abdom Imaging2003;28:72-4

[21] McGee EE,Petrick JL.Smoking, alcohol, and biliary tract cancer risk: a pooling project of 26 prospective studies.J Natl Cancer Inst2019;111:1263-78 PMCID:PMC6910180

[22] Welzel TM,Zeuzem S,Davila JA.Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.Hepatology2011;54:463-71 PMCID:PMC4141525

[23] Kubo S,Takemura S.Characteristics of printing company workers newly diagnosed with occupational cholangiocarcinoma.J Hepatobiliary Pancreat Sci2014;21:809-17

[24] Bergquist A,Olsson R.Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.J Hepatol2002;36:321-7

[25] Lee YM.Primary sclerosing cholangitis.N Engl J Med1995;332:924-33

[26] Claessen MM,Tytgat KM,van Buuren HR.High lifetime risk of cancer in primary sclerosing cholangitis.J Hepatol2009;50:158-64

[27] Lipsett PA,Colombani PM,Cameron JL.Choledochal cyst disease. A changing pattern of presentation.Ann Surg1994;220:644-52 PMCID:PMC1234452

[28] Khan SA,Davidson BR.Cholangiocarcinoma.Lancet2005;366:1303-14

[29] Roukounakis N,Tzourmakliotis D,McCarty TM.Biliary tract malignancy and abnormal pancreaticobiliary junction in a Western population.J Gastroenterol Hepatol2007;22:1949-52

[30] Watanapa P.Liver fluke-associated cholangiocarcinoma.Br J Surg2002;89:962-70

[31] Shaib YH,Davila JA,McGlynn KA.Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study.Gastroenterology2005;128:620-6

[32] Kobayashi M,Saitoh S.Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis.Cancer2000;88:2471-7

[33] Hsing AW,Rashid A.Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China.Int J Cancer2008;122:1849-53

[34] Mecklin JP,Virolainen M.The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma.Cancer1992;69:1112-4

[35] Lee SS,Lee SK.Clinicopathologic review of 58 patients with biliary papillomatosis.Cancer2004;100:783-93

[36] Yamada A,Komaki F,Zullow S.Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.Lancet Oncol2018;19:758-67

[37] Chen XX,Cheng JW.BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.Cell Death Dis2018;9:1036 PMCID:PMC6179995

[38] Chapman RW.Risk factors for biliary tract carcinogenesis.Ann Oncol1999;10 Suppl 4:308-11

[39] Akiba J,Hattori S.Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.Am J Surg Pathol2013;37:496-505

[40] Labib PL,Pereira SP.Molecular pathogenesis of cholangiocarcinoma.BMC Cancer2019;19:185 PMCID:PMC6394015

[41] Jones H,Francis H.Bile acid signaling and biliary functions.Acta Pharm Sin B2015;5:123-8 PMCID:PMC4629225

[42] Chen B,Ho TT,Mo YY.ERK-mediated NF-κB activation through ASIC1 in response to acidosis.Oncogenesis2016;5:e279 PMCID:PMC5177778

[43] Araki K,Suzuki H.E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma.Br J Cancer2011;105:1885-93 PMCID:PMC3251878

[44] Ogasawara S.Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines.Hepatol Res2001;20:97-113

[45] Leelawat K,Tepaksorn P.Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met.J Surg Res2006;136:78-84

[46] Sirica AE.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.World J Gastroenterol2008;14:7033-58 PMCID:PMC2776834

[47] Network NCC. Hepatobiliary cancers v2.2021. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf [Last accessed on 15 Nov 2021]

[48] Bridgewater J,Khan SA.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.J Hepatol2014;60:1268-89

[49] Lamarca A,Chander A.¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis.J Hepatol2019;71:115-29

[50] Masselli G.Hilar cholangiocarcinoma: MRI/MRCP in staging and treatment planning.Abdom Imaging2008;33:444-51

[51] Tsao JI,Kamiya J.Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience.Ann Surg2000;232:166-74 PMCID:PMC1421125

[52] Rajagopalan V,Grossbard ML.Gallbladder and biliary tract carcinoma: a comprehensive update, part 1.Oncology (Williston Park)2004;18:889-96

[53] Ebata T,Kamiya J,Nagasaka T.Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases.Ann Surg2003;238:720-7 PMCID:PMC1356151

[54] Hemming AW,Fujita S,Howard RJ.Surgical management of hilar cholangiocarcinoma.Ann Surg2005;241:693-9; discussion 699-702 PMCID:PMC1357124

[55] Mizuno T,Yokoyama Y.Combined vascular resection for locally advanced perihilar cholangiocarcinoma.Ann Surg2020;

[56] Sano T,Senda Y,Nimura Y.Assessing resectability in cholangiocarcinoma.Hepat Oncol2014;1:39-51 PMCID:PMC6114008

[57] Mansour JC,Crane CH,Nagino M.Hilar cholangiocarcinoma: expert consensus statement.HPB (Oxford)2015;17:691-9 PMCID:PMC4527854

[58] Liu F,Wei Y.Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not?.Dig Dis Sci2011;56:663-72

[59] Mehrabi A,Ghamarnejad O.Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma.Eur J Radiol2020;125:108897

[60] Laurent A,Cherqui D.Cholangiocarcinoma: preoperative biliary drainage (Con).HPB (Oxford)2008;10:126-9 PMCID:PMC2504392

[61] Nimura Y.Preoperative biliary drainage before resection for cholangiocarcinoma (Pro).HPB (Oxford)2008;10:130-3 PMCID:PMC2504393

[62] Moole H,Puli SR.Efficacy of preoperative biliary drainage in malignant obstructive jaundice: a meta-analysis and systematic review.World J Surg Oncol2016;14:182 PMCID:PMC4940848

[63] Scheufele F,Demir IE.Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: a meta-analysis of current literature.Surgery2017;161:939-50

[64] Iacono C,Campagnaro T,Valdegamberi A.Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks.Ann Surg2013;257:191-204

[65] Dumonceau JM,Papanikolaou IS.Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - updated October 2017.Endoscopy2018;50:910-30

[66] Paik WH,Hwang JH.Preoperative biliary drainage in hilar cholangiocarcinoma: when and how?.World J Gastrointest Endosc2014;6:68-73 PMCID:PMC3952162

[67] Hameed A,Chiou J.Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma - a systematic review and meta-analysis.HPB (Oxford)2016;18:400-10 PMCID:PMC4857062

[68] Al Mahjoub A,Fohlen A.Preoperative biliary drainage in patients with resectable perihilar cholangiocarcinoma: is percutaneous transhepatic biliary drainage safer and more effective than endoscopic biliary drainage?.J Vasc Interv Radiol2017;28:576-82

[69] Coelen RJS,Wiggers JK.Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial.Lancet Gastroenterol Hepatol2018;3:681-90

[70] Hwang S,Song GW.Quantified risk assessment for major hepatectomy via the indocyanine green clearance rate and liver volumetry combined with standard liver volume.J Gastrointest Surg2015;19:1305-14

[71] Adam R,Azoulay D,Bismuth H.Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors.Ann Surg2000;232:777-85 PMCID:PMC1421270

[72] Lam VW,Johnston E,Pleass HC.A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases.HPB (Oxford)2013;15:483-91 PMCID:PMC3692017

[73] Popescu GA,Grigorie RT,Apavaloaie CA.GOOD TO KNOW: the ALPPS procedure - embracing a new technique.Chirurgia (Bucur)2017;112:332-41

[74] Liu Y,Gu S.A systematic review and meta-analysis of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) versus traditional staged hepatectomy.Medicine (Baltimore)2019;98:e15229 PMCID:PMC6485722

[75] May BJ.Portal vein embolization: rationale, technique, and current application.Semin Intervent Radiol2012;29:81-9 PMCID:PMC3444878

[76] Abulkhir A,Healey AJ.Preoperative portal vein embolization for major liver resection: a meta-analysis.Ann Surg2008;247:49-57

[77] Akateh C,Pawlik TM.Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma.World J Hepatol2020;12:693-708 PMCID:PMC7643214

[78] Kato A,Ohtsuka M.Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery.Ann Surg Oncol2015;22 Suppl 3:S1093-9

[79] Le Roy B,Pittau G.Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma.Br J Surg2018;105:839-47

[80] Rizzo A.Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review.Cancer Treat Res Commun2021;27:100354

[81] Konstantinidis IT,Do RK.Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.Cancer2016;122:758-65 PMCID:PMC4764409

[82] Cercek A,Tan BR.Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial.JAMA Oncol2020;6:60-7 PMCID:PMC6824231

[83] Imamura H,Kokudo N.One thousand fifty-six hepatectomies without mortality in 8 years.Arch Surg2003;138:1198-206; discussion 1206

[84] Dimick JB,Knol JA.Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database.Arch Surg2003;138:185-91

[85] Colavita PD,Belyansky I.Regionalization and outcomes of hepato-pancreato-biliary cancer surgery in USA.J Gastrointest Surg2014;18:532-41

[86] Kinoshita H,Hirohashi K,Yamasaki O.Preoperative portal vein embolization for hepatocellular carcinoma.World J Surg1986;10:803-8

[87] Ebata T,Yokoyama Y,Sugawara G.Surgical resection for Bismuth type IV perihilar cholangiocarcinoma.Br J Surg2018;105:829-38

[88] Abbas S.Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma.HPB (Oxford)2013;15:492-503 PMCID:PMC3692018

[89] Leen E,Moug SJ.Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection?.Ann Surg2006;243:236-40 PMCID:PMC1448920

[90] Yin L,Zhu H,Zhang X.Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study.Sci Rep2021;11:12166 PMCID:PMC8190174

[91] Ribero D,Guglielmi A.Italian Intrahepatic Cholangiocarcinoma Study GroupSurgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients.Arch Surg2012;147:1107-13

[92] Spolverato G,Kim Y.The Impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma.Ann Surg Oncol2015;22:4020-8

[93] Raab R,Oldhafer KJ,Lang H.Ex-vivo resection techniques in tissue-preserving surgery for liver malignancies.Langenbecks Arch Surg2000;385:179-84

[94] Zawistowski M,Jakubczyk M.Outcomes of ex vivo liver resection and autotransplantation: a systematic review and meta-analysis.Surgery2020;168:631-42

[95] Farges O,Boleslawski E.Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group.Ann Surg2011;254:824-29; discussion 830

[96] Shimada K,Sakamoto Y,Kosuge T.Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases.J Surg Oncol2007;96:160-5

[97] Tamandl D,Gruenberger B,Klinger M.Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma.Ann Surg Oncol2008;15:2787-94

[98] Hong JC,Duffy JP.Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center.Arch Surg2011;146:683-9

[99] Nuzzo G,Ardito F.Italian Chapter of the International Hepato-Pancreato-Biliary AssociationImprovement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients.Arch Surg2012;147:26-34

[100] Hasegawa S,Fujii H,Shimahara Y.Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications.World J Surg2007;31:1256-63

[101] Zhang XF,Bagante F.The impact of intraoperative re-resection of a positive bile duct margin on clinical outcomes for hilar cholangiocarcinoma.Ann Surg Oncol2018;25:1140-9

[102] Neuhaus P,Bechstein WO.Extended resections for hilar cholangiocarcinoma.Ann Surg1999;230:808-18; discussion 819 PMCID:PMC1420945

[103] Edge SB.The American Joint Committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.Ann Surg Oncol2010;17:1471-4

[104] Lim JH,Choi SH,Choi JS.Liver resection for Bismuth type I and Type II hilar cholangiocarcinoma.World J Surg2013;37:829-37

[105] de Jong MC,Sotiropoulos GC.Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.J Clin Oncol2011;29:3140-5

[106] Zhang XF,Kimbrough CW.Lymphadenectomy for intrahepatic cholangiocarcinoma: has nodal evaluation been increasingly adopted by surgeons over time?.J Gastrointest Surg2018;22:668-75

[107] Ercolani G,Ravaioli M.The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy.Ann Surg2004;239:202-9 PMCID:PMC1356213

[108] Kitagawa Y,Kamiya J.Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection.Ann Surg2001;233:385-92 PMCID:PMC1421255

[109] Kim SH,Choi GH,Kim KS.Extent of lymph node dissection for accurate staging in intrahepatic cholangiocarcinoma.J Gastrointest Surg2021;

[110] Amin MB,Edge SB.The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.CA Cancer J Clin2017;67:93-9

[111] Marsh Rde W,Bajaj S.Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology.J Surg Oncol2012;106:332-8

[112] DeOliveira ML,Clavien PA.Advances in liver surgery for cholangiocarcinoma.Curr Opin Gastroenterol2013;29:293-8

[113] Razumilava N.Classification, diagnosis, and management of cholangiocarcinoma.Clin Gastroenterol Hepatol2013;11:13-21.e1; quiz e3-4 PMCID:PMC3596004

[114] Loehrer AP,Nakeeb A,Pitt HA.Cholangiocarcinoma: are North American surgical outcomes optimal?.J Am Coll Surg2013;216:192-200

[115] Ebata T,Igami T.Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients.Ann Surg2012;256:297-305

[116] Hemming AW,Fujita S.Combined resection of the liver and pancreas for malignancy.J Am Coll Surg2010;210:808-14, 814-6

[117] Sarmiento JM,Sarr MG.Periampullary cancers: are there differences?.Surg Clin North Am2001;81:543-55

[118] Askew J.Review of the investigation and surgical management of resectable ampullary adenocarcinoma.HPB (Oxford)2013;15:829-38 PMCID:PMC4503279

[119] Cloyd JM,Pawlik TM.The landmark series: intrahepatic cholangiocarcinoma.Ann Surg Oncol2020;27:2859-65

[120] Gamboa AC.The landmark series: gallbladder cancer.Ann Surg Oncol2020;27:2846-58

[121] Shroff RT,Bachini M.Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline.J Clin Oncol2019;37:1015-27

[122] Cloyd JM.Adjuvant therapy for biliary tract cancers: new evidence to resolve old questions.J Oncol Pract2018;14:723-4

[123] Horgan AM,Walter T.Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.J Clin Oncol2012;30:1934-40

[124] Ghidini M,Botticelli A.Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis.HPB (Oxford)2017;19:741-8

[125] Takada T,Yasuda H.Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary TractIs postoperative adjuvant chemotherapy useful for gallbladder carcinoma?.Cancer2002;95:1685-95

[126] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81

[127] André T,Fartoux L.Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.Br J Cancer2008;99:862-7 PMCID:PMC2538748

[128] Edeline J,Bertaut A.Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study.J Clin Oncol2019;37:658-67

[129] Primrose JN,Palmer DH.Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.Lancet Oncol2019;20:663-73

[130] Ebata T,Konishi M.Bile Duct Cancer Adjuvant Trial (BCAT) Study GroupRandomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.Br J Surg2018;105:192-202

[131] Itano O,Kishida N.A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).BMC Cancer2020;20:688 PMCID:PMC7379785

[132] Ben-Josef E,El-Khoueiry AB.SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma.J Clin Oncol2015;33:2617-22 PMCID:PMC4534524

[133] Hyder O,Salem R.Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.Ann Surg Oncol2013;20:3779-86

[134] Sullivan RD,Watkins Jr E.Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion.N Engl J Med1964;270(7):321-327

[135] Thiels CA.Hepatic artery infusion pumps.J Surg Oncol2020;122:70-7

[136] Jarnagin WR,Gultekin DH.Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.Ann Oncol2009;20:1589-95 PMCID:PMC2731015

[137] Zamora-Valdes D.Liver transplant for cholangiocarcinoma.Gastroenterol Clin North Am2018;47:267-80

[138] Becker NS,Barshes NR,Goss JA.Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period.J Gastrointest Surg2008;12:117-22

[139] Goldstein RM,Tillery GW.Is liver transplantation indicated for cholangiocarcinoma?.Am J Surg1993;166:768-72

[140] Lunsford KE,Heyne K.Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.Lancet Gastroenterol Hepatol2018;3:337-48

[141] Pichlmayr R,Oldhafer KJ.Role of liver transplantation in the treatment of unresectable liver cancer.World J Surg1995;19:807-13

[142] Sapisochin G,Rubbia-Brandt L.iCCA International ConsortiumLiver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment.Hepatology2016;64:1178-88

[143] Heimbach JK,Alberts SR.Transplantation for hilar cholangiocarcinoma.Liver Transpl2004;10:S65-8

[144] Rea DJ,Rosen CB.Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma.Ann Surg2005;242:451-8; discussion 458-61 PMCID:PMC1357753

[145] Rosen CB,Gores GJ.Liver transplantation for cholangiocarcinoma.Transpl Int2010;23:692-7

[146] Darwish Murad S,Harnois DM.Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers.Gastroenterology2012;143:88-98.e3; quiz e14 PMCID:PMC3846443

[147] Abu Hilal M,Dagher I.The southampton consensus guidelines for laparoscopic liver surgery: from indication to implementation.Ann Surg2018;268:11-8

[148] Wakabayashi G,Geller DA.Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka.Ann Surg2015;261:619-29

[149] Buell JF,Geller DA.World Consensus Conference on Laparoscopic SurgeryThe international position on laparoscopic liver surgery: the Louisville statement, 2008.Ann Surg2009;250:825-30

[150] Lee W,Kim JY.Comparison of perioperative and oncologic outcomes between open and laparoscopic liver resection for intrahepatic cholangiocarcinoma.Surg Endosc2016;30:4835-40

[151] Ma D,Wang J.Laparoscopic versus open surgery for hilar cholangiocarcinoma: a retrospective cohort study on short-term and long-term outcomes.Surg Endosc2021;

[152] Martin SP,Wach MM.Laparoscopic approach to intrahepatic cholangiocarcinoma is associated with an exacerbation of inadequate nodal staging.Ann Surg Oncol2019;26:1851-7 PMCID:PMC8132107

[153] Machairas N,Schizas D,Nikiteas N.Meta-analysis of laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma.Updates Surg2021;73:59-68

[154] Ziogas IA,Giannis D.Laparoscopic versus open hepatectomy for intrahepatic cholangiocarcinoma: an individual patient data survival meta-analysis.Am J Surg2021;222:731-8

[155] Wiggers JK,Cieslak KP.Postoperative mortality after liver resection for perihilar cholangiocarcinoma: development of a risk score and importance of biliary drainage of the future liver remnant.J Am Coll Surg2016;223:321-31.e1 PMCID:PMC4961586

[156] Cillo U,Furlanetto A,Gringeri E.Robotic hepatectomy and biliary reconstruction for perihilar cholangiocarcinoma: a pioneer western case series.Updates Surg2021;73:999-1006 PMCID:PMC8184707